This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Frank, D. H. Articles by Alberts, D. S. Search for Related Content PubMed PubMed Citation Articles by Frank, D. H. Articles by Alberts, D. S.

Effects of a High-Selenium Yeast Supplement on Celecoxib Plasma Levels

A Randomized Phase II Trial

¹ Arizona Cancer Center, ² Section of Hematology and Oncology, Department of Medicine, College of Medicine, ³ College of Public Health, ⁴ College of Pharmacy, and ⁵ College of Medicine, University of Arizona, Tucson, Arizona

A combination of celecoxib and selenium was used in a randomized double-blind Phase II trial as a preliminary study to a multicenter Phase III colorectal cancer chemoprevention trial using these two agents together. The purpose of this trial was to determine whether high-selenium baker’s yeast [(Saccharomyces cerevisiae) 200 µg once daily] in combination with celecoxib (400 mg once daily) altered the steady-state plasma concentration of celecoxib or produced clinically significant toxicities. Seventy-three healthy subjects (ages 40–75 years) were recruited to the 6-week study from the general local population and were randomized to either the celecoxib plus selenized baker’s yeast group or the celecoxib plus placebo group after a 2-week run in period of celecoxib only. Blood samples were taken at baseline (to document that there was no evidence of celecoxib intake), after the 2-week run-in period on celecoxib to verify steady-state blood levels of this agent, and at end of study (4 weeks postrandomization). Toxicities were monitored at 2 weeks after initiation of celecoxib, at 4 weeks after initiation, and at the end of the study. Blood level concentrations of celecoxib did not differ between the two groups as determined by high-performance liquid chromatography analysis nor were there significant differences in blood chemistry values between the two groups. Subjects’ self-report of general physical toxicities was uncommon and limited to National Cancer Institute toxicity grade 2 or less; however, 2 female participants (3%) were removed from the study medications because of grade 2 edema and significant weight gain after 2 and 2.5 weeks of celecoxib administration. In conclusion, high-selenium yeast and celecoxib can be taken at the described doses with minimum short-term negative effects. In future Phase III chemoprevention trials of celecoxib, weight gain should be carefully monitored, and participants should be made aware of this potential side effect before study entry.

This article has been cited by other articles:

				D. S. Alberts, J. D. Potter, M. E. Martinez, L. M. Hess, A. Stopeck, and P. Lance What Happened to the Coxibs on the Way to the Cardiologist? Cancer Epidemiol. Biomarkers Prev., March 1, 2005; 14(3): 555 - 556. [Full Text] [PDF]

				A.-C. Goulet, M. Chigbrow, P. Frisk, and M. A. Nelson Selenomethionine induces sustained ERK phosphorylation leading to cell-cycle arrest in human colon cancer cells Carcinogenesis, January 1, 2005; 26(1): 109 - 117. [Abstract] [Full Text] [PDF]